Samsung Epis Holdings, the holding company overseeing Samsung's biopharmaceutical investments, officially opened its China Research & Development Center Tuesday, marking the launch of its first overseas research and development (R&D) base. The company held an opening ceremony in Beijing's Changping District for the new center, registered locally as Samsung Bioepis, and began full-scale research operations, according to a company statement. The Beijing center was established as a field-specialized unit to build a technology platform centered on antibody-drug conjugates — a class of cancer treatment that pairs a targeting antibody with a cytotoxic drug through a chemical linker, allowing the drug to attack cancer cells more precisely while limiting side effects to healthy tissue — and to strengthen the company's capabilities in new drug development. Changping District is home to the Zhongguancun Life Science Park, a biotechnology hub, and sits near Peking University and Tsinghua University, giving the site access to strong research infrastructure and talent, the company said. "With the